Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345252 · ClinicalTrials.gov registry record · Phase 3
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 632
- Enrollment target
NCT02345252 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 632 participants.
The verdict
NCT02345252, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 632 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir disoproxil fumarate (TDF) FDC (FTC/RPV/TDF) in virologically suppressed HIV-1 infected participants.
Interventions
- DRUG FTC/RPV/TDF
- DRUG FTC/RPV/TAF
- DRUG FTC/RPV/TAF Placebo
- DRUG FTC/RPV/TDF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 632 participants |
| Start Date | 2015-01-26 |
| Est. Completion | 2019-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345252
The ClinicalTrials.gov registry entry for NCT02345252 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 632 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FTC/RPV/TDF is the first listed.
NCT02345252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345252 about?
NCT02345252 is a clinical study titled "Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)". The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir disoproxil fumarate (TDF) FDC (FTC/RPV/TDF) in virologically suppressed HIV-1 ...
What is the current status of trial NCT02345252?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 632 participants. The study started on 2015-01-26. Estimated completion is 2019-01-09.
What interventions are being tested in trial NCT02345252?
The interventions under investigation include: FTC/RPV/TDF (DRUG), FTC/RPV/TAF (DRUG), FTC/RPV/TAF Placebo (DRUG), FTC/RPV/TDF Placebo (DRUG).
Who is sponsoring clinical trial NCT02345252?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.